Press releases
- Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
- Hansa Biopharma: increase in number of shares and votes
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma publishes 2023 Annual and Sustainability Reports
More ▼
Key statistics
On Wednesday, Hansa Biopharma AB (0RC7:LSE) closed at 42.21, -24.63% below its 52-week high of 56.00, set on May 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 40.12 |
---|---|
High | 42.82 |
Low | 40.28 |
Bid | 41.16 |
Offer | 43.26 |
Previous close | 42.21 |
Average volume | 2.83k |
---|---|
Shares outstanding | 63.15m |
Free float | 59.05m |
P/E (TTM) | -- |
Market cap | 2.54bn SEK |
EPS (TTM) | -16.07 SEK |
Data delayed at least 20 minutes, as of May 22 2024 17:32 BST.
More ▼